» Articles » PMID: 34386503

PPOS Protocol Effectively Improves the IVF Outcome Without Increasing the Recurrence Rate in Early Endometrioid Endometrial Cancer and Atypical Endometrial Hyperplasia Patients After Fertility Preserving Treatment

Overview
Specialty General Medicine
Date 2021 Aug 13
PMID 34386503
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

To investigate the effectiveness and recurrence risk of different ovulation stimulation protocols in early-stage endometrioid endometrial cancer (EEC) and atypical endometrial hyperplasia (AEH) patients after successful fertility preserving treatment. A retrospective review of clinical files between June 2012 and July 2018. University hospital. Ninety seven women (74 AEH and 23 early-stage EEC patients) underwent fertilization (IVF) and frozen-thawed embryo transfer (FET) after successful fertility preserving treatment. All patients received megestrol acetate which was initiated immediately after AEH or EEC diagnosis by hysteroscopy. Fertility treatment was initiated after confirmation of complete response by two consecutive hysteroscopic evaluations and endometrium biopsy in a 3-month interval. Women with tubal factors underwent IVF treatment directly. Women who failed to conceive spontaneously within 12 months or after other infertility treatments like ovulation induction for 6 consecutive months or 2 consecutive artificial insemination failures were also offered IVF treatment. The clinical and laboratory embryo data, clinical pregnancy outcomes and endometrial disease recurrence rates. Compared with the standard regimen group, the good-quality embryo rate was higher in progestin primed ovarian stimulation (PPOS) regimen group ( = 0.034). Univariate analysis showed significant differences in age ( = 0.033), treatment time of endometrial lesions ( < 0.001), and duration of Gn treatment ( = 0.018) between the recurrent and non-recurrent groups. In the adjusted model of multivariate logistic regression analysis, the age ( = 0.014) at ovulation induction and treatment time of endometrial lesions ( < 0.001) were significantly correlated with the recurrence of endometrial disease. The PPOS protocol is a feasible and safe strategy to stimulate ovulation during IVF after fertility preservation therapy, and the age at ovulation induction and treatment time of endometrial lesions are two stable predictors of recurrence in endometrial diseases.

Citing Articles

Analysis of assisted reproductive outcomes for gynecologic cancer survivors: a retrospective study.

Lin J, Yang T, Li L, Sun X, Li H Reprod Biol Endocrinol. 2024; 22(1):97.

PMID: 39107798 PMC: 11301938. DOI: 10.1186/s12958-024-01272-0.


Current research of Assisted Reproductive Technology for women with early endometrial cancer and atypical endometrial hyperplasia after conservative treatment.

Jiang Y, Lin Y, Chen C, Li Y, Xie H, Zheng B Front Endocrinol (Lausanne). 2024; 15:1377396.

PMID: 38919483 PMC: 11196392. DOI: 10.3389/fendo.2024.1377396.


Pregnancy outcomes in infertile patients with endometrial hyperplasia with or without atypia undergoing fertilization: the early-follicular long protocol is superior to midluteal long protocol.

An H, Li T, Huang K, Shi H, Wang C, Chu T Front Endocrinol (Lausanne). 2024; 15:1314432.

PMID: 38449849 PMC: 10916507. DOI: 10.3389/fendo.2024.1314432.


Successful delivery after in vitro fertilization-embryo transfer in a woman with metachronous primary cancer of ovary and endometrium: a case report.

Tian Y, Liang Y, Yang X BMC Pregnancy Childbirth. 2023; 23(1):677.

PMID: 37726657 PMC: 10507849. DOI: 10.1186/s12884-023-05973-z.


Segmented in vitro fertilization and frozen embryo transfer in levonorgestrel-releasing intrauterine device treated patients with endometrial cancer.

Wei H, Pan N, Wang Y, Ma C Arch Gynecol Obstet. 2023; 308(6):1845-1852.

PMID: 37656272 PMC: 10579151. DOI: 10.1007/s00404-023-07170-x.


References
1.
Yamagami W, Susumu N, Makabe T, Sakai K, Nomura H, Kataoka F . Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?. J Gynecol Oncol. 2018; 29(2):e21. PMC: 5823982. DOI: 10.3802/jgo.2018.29.e21. View

2.
Giampaolino P, Di Spiezio Sardo A, Mollo A, Raffone A, Travaglino A, Boccellino A . Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study. J Minim Invasive Gynecol. 2018; 26(4):648-656. DOI: 10.1016/j.jmig.2018.07.001. View

3.
Tangjitgamol S, Manusirivithaya S, Hanprasertpong J . Fertility-sparing in endometrial cancer. Gynecol Obstet Invest. 2009; 67(4):250-68. DOI: 10.1159/000209324. View

4.
Huang J, Xie Q, Lin J, Lu X, Wang N, Gao H . Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF: a retrospective cohort study. Drug Des Devel Ther. 2019; 13:2553-2563. PMC: 6667350. DOI: 10.2147/DDDT.S210228. View

5.
Peng X, Yu M, Li L, Fu W, Chen H, Sun X . Effects of euploid blastocyst morphological development on reproductive outcomes. Reprod Biol. 2020; 20(4):496-500. DOI: 10.1016/j.repbio.2020.08.002. View